Literature DB >> 28396317

4PD Functionalized Dendrimers: A Flexible Tool for In Vivo Gene Silencing of Tumor-Educated Myeloid Cells.

Serena Zilio1, Jennifer L Vella1, Adriana C De la Fuente1, Pirouz M Daftarian1, Donald T Weed2, Angel Kaifer3, Ilaria Marigo4, Kevin Leone4, Vincenzo Bronte5, Paolo Serafini6.   

Abstract

Myeloid cells play a key role in tumor progression and metastasis by providing nourishment and immune protection, as well as facilitating cancer invasion and seeding to distal sites. Although advances have been made in understanding the biology of these tumor-educated myeloid cells (TEMCs), their intrinsic plasticity challenges our further understanding of their biology. Indeed, in vitro experiments only mimic the in vivo setting, and current gene-knockout technologies do not allow the simultaneous, temporally controlled, and cell-specific silencing of multiple genes or pathways. In this article, we describe the 4PD nanoplatform, which allows the in vivo preferential transfection and in vivo tracking of TEMCs with the desired RNAs. This platform is based on the conjugation of CD124/IL-4Rα-targeting peptide with G5 PAMAM dendrimers as the loading surface and can convey therapeutic or experimental RNAs of interest. When injected i.v. in mice bearing CT26 colon carcinoma or B16 melanoma, the 4PD nanoparticles predominantly accumulate at the tumor site, transfecting intratumoral myeloid cells. The use of 4PD to deliver a combination of STAT3- and C/EBPβ-specific short hairpin RNA or miR-142-3p confirmed the importance of these genes and microRNAs in TEMC biology and indicates that silencing of both genes is necessary to increase the efficacy of immune interventions. Thus, the 4PD nanoparticle can rapidly and cost effectively modulate and assess the in vivo function of microRNAs and mRNAs in TEMCs.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28396317     DOI: 10.4049/jimmunol.1600833

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Enhancing cancer immunotherapy with nanomedicine.

Authors:  Darrell J Irvine; Eric L Dane
Journal:  Nat Rev Immunol       Date:  2020-01-31       Impact factor: 53.106

2.  Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis.

Authors:  Chiara Musiu; Simone Caligola; Alessandra Fiore; Alessia Lamolinara; Cristina Frusteri; Francesco Domenico Del Pizzo; Francesco De Sanctis; Stefania Canè; Annalisa Adamo; Francesca Hofer; Roza Maria Barouni; Andrea Grilli; Serena Zilio; Paolo Serafini; Evelina Tacconelli; Katia Donadello; Leonardo Gottin; Enrico Polati; Domenico Girelli; Ildo Polidoro; Piera Amelia Iezzi; Domenico Angelucci; Andrea Capece; Ying Chen; Zheng-Li Shi; Peter J Murray; Marco Chilosi; Ido Amit; Silvio Bicciato; Manuela Iezzi; Vincenzo Bronte; Stefano Ugel
Journal:  Cell Death Differ       Date:  2021-09-13       Impact factor: 12.067

3.  Aptamers against mouse and human tumor-infiltrating myeloid cells as reagents for targeted chemotherapy.

Authors:  Adriana De La Fuente; Serena Zilio; Jimmy Caroli; Dimitri Van Simaeys; Emilia M C Mazza; Tan A Ince; Vincenzo Bronte; Silvio Bicciato; Donald T Weed; Paolo Serafini
Journal:  Sci Transl Med       Date:  2020-06-17       Impact factor: 19.319

Review 4.  Generation of Myeloid Cells in Cancer: The Spleen Matters.

Authors:  Chong Wu; Qiaomin Hua; Limin Zheng
Journal:  Front Immunol       Date:  2020-06-05       Impact factor: 7.561

Review 5.  Modulation of Immunosuppression by Oligonucleotide-Based Molecules and Small Molecules Targeting Myeloid-Derived Suppressor Cells.

Authors:  Jihyun Lim; Aram Lee; Hee Gu Lee; Jong-Seok Lim
Journal:  Biomol Ther (Seoul)       Date:  2020-01-01       Impact factor: 4.634

6.  Systematic Review of Cancer Targeting by Nanoparticles Revealed a Global Association between Accumulation in Tumors and Spleen.

Authors:  Andrey S Drozdov; Petr I Nikitin; Julian M Rozenberg
Journal:  Int J Mol Sci       Date:  2021-12-01       Impact factor: 5.923

Review 7.  Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy.

Authors:  Francesco De Sanctis; Annalisa Adamo; Stefania Canè; Stefano Ugel
Journal:  Semin Immunopathol       Date:  2022-09-26       Impact factor: 11.759

Review 8.  Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.

Authors:  Mithunah Krishnamoorthy; Lara Gerhardt; Saman Maleki Vareki
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

9.  CCR1 and CCR5 mediate cancer-induced myelopoiesis and differentiation of myeloid cells in the tumor.

Authors:  Serena Zilio; Silvio Bicciato; Donald Weed; Paolo Serafini
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 12.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.